We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD First positive reimbursement decision worldwide for LYTENAVA™; First launch...
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD UK MHRA marketing authorization follows recent European...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0.31 | 0.472 | 0.296 | 11451 | 0.37782412 | DE |
156 | 0 | 0 | 0.26 | 0.81 | 0.185 | 66891 | 0.35783749 | DE |
260 | 0 | 0 | 0.26 | 0.81 | 0.185 | 66891 | 0.35783749 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions